Cardiff Oncology, Inc.

Cardiff Oncology believes it is on track to upend the standard of care for patients with RAS-mutated metastatic colorectal cancer (mCRC), based on positive early Phase II data testing the PLK1 inhibit

Cardiff Oncology, Inc. expects to release top-line data from a Phase II study of its PLK1 inhibitor onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) around mid-2024, but data

Cardiff Oncology, Inc. presented updates from the ongoing Phase Ib/II clinical trial for its Polo-like kinase-1 (PLK1) inhibitor onvansertib at the European Society for Medical Oncology (ESMO) meetin

BMS’s Opdivo + Chemo Shines In Neoadjuvant Lung Cancer Elaborating on top-line data it announced last October, Bristol Myers Squibb Company reported on 10 April that Opdivo can yield pathologic comp